Ignite Creation Date:
2025-12-24 @ 7:00 PM
Ignite Modification Date:
2025-12-25 @ 4:33 PM
Study NCT ID:
NCT01368757
Status:
UNKNOWN
Last Update Posted:
2015-03-09
First Post:
2011-05-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Organization:
Study Overview
Official Title:
A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
Status:
UNKNOWN
Status Verified Date:
2015-03
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In a phase I study the investigators plan to investigate safety and toxicity of lenalidomide in patients with Chronic Myelomonocytic Leukemia (CMML). A phase II study will be started once an optimal dose has been found. The primary endpoint will concern the efficacy of lenalidomide in patients with CMML according to the WHO diagnostic criteria.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2009-017147-33 | EUDRACT_NUMBER | None | View |